Teva Pharmaceuticals is trading 4.12% down at ILA 12,320.00 on October 21, 2026, with no clear cause established by the available evidence.

  • Available company coverage highlights positive duvakitug study data and an earlier FDA approval, but identifies no new negative company-specific catalyst.
  • Healthcare is up 2.12%, moving in the opposite direction; the sector context does not explain Teva’s decline.